BioCardia, Inc. BCDA 深 沪
已收盘 04-02 16:00:00 美东时间
1.20
+0.040
+3.45%
华盛通- 最 高1.20
- 今 开1.20
- 成交量 9.40万股
- 最 低 1.1401
- 昨 收 1.16
- 总市值 1312.84万
- 52周最高 3.20
- 市盈率 静 --
- 换手率 0.86%
- 52周最低 1.00
- 委 比 50.35%
- 总股本 1094.04万
- 历史最高 129.00
- 量 比 2.09
- 振 幅 5.16%
- 历史最低 1.00
- 每 手 1
- 风险率 0.47%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BioCardia Files Request For FDA Meeting Related To Approval For CardiAMP System For Ischemic Chronic Heart Failure
BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported submission to United States Food and Drug
04-02 22:15
BioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP® System in Ischemic Heart Failure
BioCardia, a global leader in cellular therapies, submitted data from its CardiAMP HF clinical study to the FDA and plans to meet with the agency to discuss accelerated approval for the CardiAMP System to treat ischemic chronic heart failure with reduced ejection fraction (HFrEF). The meeting, expected this quarter, will focus on obtaining FDA feedback on the safety, clinical response data, and potential benefits observed in the trial, particular...
04-02 14:11
BioCardia Q4 EPS $(0.06) Beats $(0.17) Estimate
BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.17) by 64.71 percent. This is a 76 percent increase over losses of $(0.25) per share from the same
03-25 04:13
Earnings Scheduled For March 24, 2026
Companies Reporting Before The Bell • Fennec Pharmaceuticals (NASDAQ:FENC) is e...
03-24 19:11
The FDA Accepts Biocardia's Pre-submission Package For The Approval Of Its Helix Transendocardial Delivery Catheter Intended For Intramyocardial Therapeutic And Diagnostic Agent Delivery
BioCardia has had preliminary meetings with both FDA Center for Devices and Radiological Health (CDRH) and FDA Center for Biological Evaluation and Research (CBER) on this submission in recent weeks. CDRH is expected to
03-17 18:06
BioCardia Late Breaking Echocardiography Clinical Results from CardiAMP HF Trial Presented at Technology and Heart Failure Therapeutics (THT)
BioCardia's Phase III clinical trial for ischemic heart failure (HFrEF) shows autologous CardiAMP cell therapy reduces pathological left ventricular remodeling, improving clinical outcomes and quality of life for treated patients. Results, presented at the Technology and Heart Failure Therapeutics conference, indicated significant reductions in left ventricular volumes, particularly for patients with elevated biomarkers of heart stress. Experts h...
03-03 13:00
BioCardia Completes Pre-Submission To FDA Under Q-Submission Program For Approval Of Helix Transendocardial Delivery Catheter For Intramyocardial Therapeutic And Diagnostic Agent Delivery
BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported it has completed its Pre-Submission to FDA under its
02-10 22:19
BioCardia Announces Late Breaking Echocardiography Results from the CardiAMP HF Trial to be Presented at Technology and Heart Failure Therapeutics (THT)
BioCardia, Inc. announced that echocardiography data from its CardiAMP Cell Therapy for heart failure has been accepted for a Late Breaking Clinical Trial Oral Presentation at the upcoming THT Meeting in Boston. Dr. Amish Raval will present the findings, which highlight the therapy's potential to address pathological ventricular remodeling in chronic ischemic HFrEF patients. CardiAMP, granted FDA Breakthrough designation, uses autologous bone mar...
02-03 13:00
BioCardia Completes Third Preliminary Clinical Consultation With Japan's PMDA On CardiAMP Cell Therapy Intended For Treatment Of HFrEF
BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announces it has completed a third preliminary clinical consultation
2025-12-16 21:08
BioCardia Q3 EPS $(0.24) Beats $(0.25) Estimate
BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.25) by 4 percent. This is a 60.66 percent increase over losses of $(0.61) per share from the same
2025-11-13 05:13
